Literature DB >> 9153540

The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus.

D D Gladman1, M B Urowitz, C H Goldsmith, P Fortin, E Ginzler, C Gordon, J G Hanly, D A Isenberg, K Kalunian, O Nived, M Petri, J Sanchez-Guerrero, M Snaith, G Sturfelt.   

Abstract

OBJECTIVE: To test the reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in the assessment of patients with SLE.
METHODS: Ten patients with SLE, representing a spectrum of damage and activity, were included. Each patient was examined by 6 of 10 physicians from 5 countries, representing 10 lupus clinics. The SLICC/ACR Damage Index was used to assess accumulated damage, and the SLEDAI was used to assess disease activity. The order of the patients and physicians was randomized according to a Youden square design.
RESULTS: The SLICC/ACR Damage Index detected differences among patients (P < 0.001). There was no detectable observer difference (P = 0.933), and there was no order effect (P = 0.261). Similar results were obtained with the SLEDAI. There was concordance in the SLICC/ACR Damage Index among observers, despite a wide spectrum of disease activity detected by the SLEDAI.
CONCLUSION: Physicians from different centers are able to assess patients with SLE in a reproducible way, using the SLEDAI to assess disease activity and the SLICC/ACR Damage Index to assess accumulated damage.

Entities:  

Mesh:

Year:  1997        PMID: 9153540     DOI: 10.1002/art.1780400506

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  129 in total

1.  Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study.

Authors:  María Del Carmen Zamora-Medina; Andrea Hinojosa-Azaola; Carlos A Nuñez-Alvarez; Angel Gabriel Vargas-Ruiz; Juanita Romero-Diaz
Journal:  Clin Rheumatol       Date:  2018-12-04       Impact factor: 2.980

2.  Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus.

Authors:  M B Urowitz; D Gladman; D Ibañez; S C Bae; J Sanchez-Guerrero; C Gordon; A Clarke; S Bernatsky; P R Fortin; J G Hanly; D J Wallace; D Isenberg; A Rahman; G S Alarcón; J T Merrill; E Ginzler; M Khamashta; O Nived; G Sturfelt; I N Bruce; K Steinsson; S Manzi; R Ramsey-Goldman; M A Dooley; A Zoma; K Kalunian; M Ramos; R F Van Vollenhoven; C Aranow; T Stoll; M Petri; P Maddison
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

3.  Differences in regional brain activation patterns assessed by functional magnetic resonance imaging in patients with systemic lupus erythematosus stratified by disease duration.

Authors:  Meggan Mackay; Mathew P Bussa; Cynthia Aranow; Aziz M Uluğ; Bruce T Volpe; Patricio T Huerta; Miklos Argyelan; Arthur Mandel; Joy Hirsch; Betty Diamond; David Eidelberg
Journal:  Mol Med       Date:  2011-09-21       Impact factor: 6.354

4.  Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus.

Authors:  April Jorge; Apinya Lertratanakul; Jungwha Lee; William Pearce; David McPherson; Trina Thompson; Emma Barinas-Mitchell; Rosalind Ramsey-Goldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-11-21       Impact factor: 4.794

5.  Clinicopathological features and outcomes of SLE patients with renal injury characterised by thrombotic microangiopathy.

Authors:  Wencui Chen; Shaoshan Liang; Ke Zuo; Liu Yang; Caihong Zeng; Weixin Hu
Journal:  Clin Rheumatol       Date:  2021-02-04       Impact factor: 2.980

6.  Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome.

Authors:  Vivian K Kawai; Ingrid Avalos; Annette Oeser; John A Oates; Ginger L Milne; Joseph F Solus; Cecilia P Chung; C Michael Stein
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-02       Impact factor: 4.794

Review 7.  How to monitor SLE in routine clinical practice.

Authors:  M M A Fernando; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

8.  Hippocampal atrophy in systemic lupus erythematosus.

Authors:  S Appenzeller; A D Carnevalle; L M Li; L T L Costallat; F Cendes
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

9.  The SLICC inception cohort for atherosclerosis.

Authors:  Murray B Urowitz; Dafna D Gladman
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

Review 10.  [Systemic lupus erythematosus. Target criteria for treatment].

Authors:  T Alexander; R Biesen; A Jacobi; B Hoyer; A Bruns; F Hiepe
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.